Oblique Therapeutics utilizes its proprietary AbiProt® technology to develop antibody-based medications targeting chronic pain and metastatic cancer, focusing on previously undruggable clinical targets. This approach aims to provide effective treatment options for patients with limited alternatives in these challenging medical conditions.
Funding
$15.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many clinically relevant targets are considered "undruggable" by conventional antibody technologies, leaving patients with chronic pain and metastatic cancer without effective treatment options. Current antibody discovery methods often fail to generate antibodies that can bind to these challenging targets.
Solution
Oblique Therapeutics is developing antibody-based medications for chronic pain and metastatic cancer by utilizing its proprietary AbiProt® technology, which is designed to target previously undruggable clinical targets. The AbiProt® technology is a novel approach to antibody discovery with the capability to generate antibodies against clinically meaningful targets that are inaccessible to traditional methods. This technology aims to provide effective treatment options for patients with limited alternatives, addressing unmet needs in challenging medical conditions. The company focuses on developing precision antibodies to create new medicines in pain, an area where breakthrough science and innovation are needed.
Target Audience
The primary target audience includes patients suffering from chronic pain and metastatic cancer who lack effective treatment options, as well as pharmaceutical companies seeking innovative antibody discovery technologies.
Features
- AbiProt® technology for antibody discovery against previously undruggable targets.
- Focus on developing antibody medicines for chronic pain and metastatic cancer.
- Generation of precision antibodies against clinically meaningful targets.
- Partnerships with leading animal health companies and pharmaceutical companies to apply the AbiProt® technology.
- Strategic collaboration with KTH Royal Institute of Technology to analyze protein structures using supercomputers.